Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary cancer immunotherapy products, announced that preclinical data using the Company’s novel drug product, INT230-6, was selected for a poster presentation at the National Cancer Institute’s annual Cancer Immunology and Immunotherapy Meeting. The conference is October 9 -10, 2014 in the Masur Auditorium at the National Institute of Health’s Clinical Center in Bethesda, Maryland. The poster is co-authored by Lewis H. Bender President & CEO of Intensity Therapeutics, Jay A. Berzofsky M.D., Ph.D., Chief of the Vaccine Branch Center for Cancer Research at the NCI and Masaki Terabe, Ph.D. Associate Scientist also at the NCI’s Vaccine Branch.
The poster’s title is: Novel cell penetrating formulation of cytotoxic agents administered intratumorally causes complete regression of large tumors and stimulation of an adaptive immune response in BALB/c syngeneic mice inoculated subcutaneously with murine CT26 colon cancer.
- INT230-6 treatment resulted in substantial improvement in survival
- Responders appear to be protected from recurrence of cancer
The poster will be available for viewing from 7:30AM EDT on Thursday, October 9, 2014, until 5:00 PM Friday October 10. The poster will also be available on the Technology page of Company’s website.